课题基金 / 基金详情

SHG based screening assay for detecting effectors of brain localized GPCRs that can be used to probe mental illness related phenotypes

SHG based screening assay for detecting effectors of brain localized GPCRs that can be used to probe mental illness related phenotypes
基于 SHG 的筛选试验,用于检测大脑局部 GPCR 的效应子,可用于探测精神疾病相关表型
批准号:
9977767
负责人:
Ben Moree
金额:
$26.09万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-05-10 至 2021-07-30

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract Biodesy has developed the Biodesy Delta device, a platform based on second harmonic generation (SHG) that allows one to measure changes in biomolecule structure upon ligand binding in real-time and in a high- throughput manner (using multi well plates). The Biodesy Delta will be used to develop a novel, high- throughput, SHG-based, commercial screening platform for identifying new binders and studying known ligands that directly modulate the structure and function of G-protein coupled receptors (GPCRs). SHG is a non-linear optical process that is highly sensitive to orientational changes of a SH-active, 370Da dye probe, covalently attached to a protein of interest, and requires very small amount of protein to get a reading. Using SHG, Biodesy has measured a range of molecular interactions between target proteins and small molecules, fragments, peptides and antibodies. To enable the study of GPCRs, we have successfully developed a prototype surface that allows tethering proteins and is resistant to detergents used to solubilize and stabilize membrane protein samples in solution. The new plate surface demonstrated minimal non-specific binding of the purified, labeled, thermostabilized, neurotensin receptor 1 (NTR1) GPCR. We have also demonstrated that SHG dye labeled NTR1 tethered to the surface remains functional by examining the binding of two control ligands to the tethered protein. In this project, we will develop a SHG assay that can be utilized for GPCRs that have not been stabilized by mutagenesis, and are relevant targets for drug discovery efforts or require a more in-depth understanding of their function. The Adenosine A2A Receptor (A2AR) will be the model GPCR, due to the large amount of structural, biophysical and biochemical data, functional assays and a non-stabilized construct that we can use for our SHG assay validation. First, we will design and test for activity with the Biodesy Delta multiple A2AR constructs that differ in the length of the C-terminal tail, which is very flexible and can interfere with binding to the surface. This will allow us to choose the optimal A2AR that retains full activity after labeling for SHG and attachment to the well surface. We will then create a version of our assay that can utilize 1536-well plates for more efficient screening of chemical libraries. Finally, we will test our assay in a proof of concept screen of a library that contains 20,000 small molecules.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金